Zepbound Dosage Chart: All 6 Doses, the FDA Titration Schedule, and What Each Step Does

Key Takeaways (4-6 bullets, will render as highlighted box)

• Zepbound (tirzepatide) is available in 6 doses: 2.5, 5, 7.5, 10, 12.5, and 15 mg, all delivered as a once-weekly subcutaneous injection.
• The FDA-labeled titration is 4 weeks at 2.5 mg, then 4 weeks at 5 mg, then 4-week increments up to 15 mg if needed.
• 5 mg, 10 mg, and 15 mg are the three "maintenance" doses with the most published efficacy data; 7.5 mg and 12.5 mg are intermediate titration steps.
• Most patients reach goal weight at 10 mg without needing to escalate further.
• Each dose is delivered as a single auto-injector pen, used the same day each week, with 7 days between injections.

Direct answer (40-60 words)

Zepbound comes in six doses: 2.5, 5, 7.5, 10, 12.5, and 15 mg. The FDA titration starts at 2.5 mg for 4 weeks, then 5 mg for 4 weeks, then escalates by 2.5 mg every 4 weeks if needed up to 15 mg. The 5, 10, and 15 mg doses are the studied maintenance doses.

Table of contents

1. The complete Zepbound dosage chart
2. The FDA titration schedule
3. What each dose is for
4. Expected weight loss at each dose
5. How long to stay at each step
6. Side-effect frequency by dose
7. Pen mechanics and how to inject
8. Storage and shelf life
9. Missed dose protocol
10. Compounded vs brand-name dosing
11. FAQ

The complete Zepbound dosage chart

(Pen colors are approximate and may change between Eli Lilly's packaging revisions. Check the label, not the color.)

All doses are delivered in a single 0.5 mL injection from a pre-filled, single-use auto-injector. The drug concentration scales with dose: 2.5 mg pens contain 5 mg/mL solution, 5 mg pens contain 10 mg/mL, and so on.

The FDA titration schedule

The labeled titration from Eli Lilly's prescribing information:

Key rules from the prescribing information:

1. Each dose escalation should be at least 4 weeks apart.
2. Escalation is not required. Patients responding well to a lower dose can hold there.
3. If side effects develop, the next escalation should be delayed.
4. Maximum dose is 15 mg/week. No higher doses are FDA-approved for Zepbound.

This schedule is conservative on purpose. The 4-week intervals give the body time to adapt to slower gastric emptying, which is the upstream cause of most GI side effects.

What each dose is for

2.5 mg. Tolerance dose only. Some weight loss may occur (2 to 4 pounds in the first 4 weeks for some patients), but this dose is not intended as a treatment endpoint. Skipping it is associated with substantially worse nausea and vomiting at higher doses.

5 mg. First true treatment dose. In SURMOUNT-1, patients who stayed at 5 mg lost 16% of body weight over 72 weeks. This is more weight loss than the maximum effect of any pre-2020 weight-loss drug. Many patients can stop titration here.

7.5 mg. Intermediate step. Sometimes used as a stable maintenance dose for patients who tolerate 5 mg well but plateau there, or as a stepping stone to 10 mg.

10 mg. The most common long-term dose. Trial weight loss (21.4%) is nearly identical to 15 mg with substantially fewer side effects. Most providers consider 10 mg the practical sweet spot.

12.5 mg. Intermediate step. Used when 10 mg has plateaued and the patient is not at goal weight, before committing to the full 15 mg dose.

15 mg. Maximum approved dose. Best for patients who need every percentage point of weight loss they can get and who tolerate the medication well at lower doses.

For patients deciding between dose targets, our most effective Zepbound dose article covers the trade-offs in detail.

Expected weight loss at each dose

From SURMOUNT-1 (Jastreboff et al., NEJM 2022) and SURMOUNT-2 (Garvey et al., Lancet 2023):

A few practical patterns:

• The first 8 to 12 weeks usually produce the fastest weight loss (1.5 to 3 lb per week).
• The middle phase (months 4 to 9) settles into 0.5 to 1.5 lb per week.
• Late phase (months 10 to 18) trends toward 0.25 to 0.75 lb per week as the body approaches a new set point.
• Patients with type 2 diabetes lose about 60 to 70% as much weight as non-diabetic patients at the same dose.
• Patients on stable thyroid replacement, mood medications, and standard hypertension medications usually do not have markedly different responses.

The numbers above are mean values across hundreds of patients. Individual response varies widely. Some patients lose 30% at 10 mg, some lose 8% at 15 mg.

How long to stay at each step

The default is 4 weeks per step, but real-world practice often differs. Common patterns:

Stay longer at 2.5 mg if:

• Side effects are heavy in week 3 or 4
• You want to take the gentlest approach
• You are sensitive to medications generally

Stay longer at 5 mg if:

• You are losing 1 to 2 pounds per week
• Goal weight is within 30 pounds
• Side effects are present but tolerable
• You want to test whether 5 mg alone gets you to goal

Stay longer at 10 mg if:

• Goal weight is in sight (within 15 to 20 pounds)
• You are losing 0.5 to 1.5 pounds per week
• Side effects of further escalation are not appealing

Move quickly through doses if:

• You have a large amount of weight to lose
• Side effects are minimal
• You need significant clinical effect quickly

Some patients spend 6 months at 5 mg, some spend 3 weeks per step. Both are reasonable depending on goals and tolerance.

Side-effect frequency by dose

Pulled from SURMOUNT-1 (Jastreboff et al., NEJM 2022):

Side effects scale with dose, but the increases are modest at each step. The most common pattern is heaviest side effects in the first 1 to 3 weeks of any dose, then gradual fade as the gut adapts.

Pen mechanics and how to inject

The Zepbound auto-injector pen is single-use, pre-filled, and includes an internal needle. The injection process:

1. Take the pen from the refrigerator. Allow 30 minutes at room temperature for comfort.
2. Inspect the medicine through the viewing window. It should be clear and colorless to slightly yellow. Do not use if cloudy, particulate, or unusually colored.
3. Choose an injection site: abdomen (avoid 2 inches around the navel), front of thigh, or back of upper arm.
4. Wipe the skin with alcohol. Allow to air dry.
5. Remove the base cap of the pen. Do not remove until ready to inject.
6. Press the pen flat against the skin at a 90-degree angle.
7. Press and hold the injection button. You will hear a click. Hold for 10 full seconds. A second click indicates the injection is complete.
8. Pull the pen straight away from the skin.
9. Dispose of the used pen in a sharps container.

Each pen contains the full prescribed dose; do not share pens or break them apart.

For a deeper walkthrough on injection technique, see our injection technique guide.

Storage and shelf life

Refrigerated (preferred): 36 to 46°F (2 to 8°C). Keep in original carton to protect from light. Stable through the labeled expiration date.

Room temperature (optional): up to 86°F (30°C) for up to 21 days. Useful for travel. Do not refrigerate again after warming.

Do not freeze. Freezing degrades tirzepatide. Discard any pen that has been frozen.

Do not shake. Vigorous shaking can damage the peptide. Gentle inversion is fine.

Light exposure: keep pens in the carton until use. Brief light exposure during injection is fine.

If a pen has been at room temperature for unknown time or above 86°F, contact the pharmacy before use.

Missed dose protocol

If you forget your weekly Zepbound injection:

• Less than 4 days late: take the dose as soon as you remember. Resume your normal weekly schedule the following week.
• More than 4 days late: skip the missed dose. Wait until your next scheduled injection day. Do not double up.

Tirzepatide has a half-life of about 5 days, which means missed weekly doses do not cause sudden withdrawal effects but can cause a temporary return of appetite. Two or more missed doses in a row can require a brief de-titration if you experience strong side effects when restarting.

If you miss multiple weeks (more than 14 days off the medication), some providers recommend re-titrating from a lower dose to avoid severe nausea on restart.

Compounded vs brand-name dosing

Compounded tirzepatide and brand-name Zepbound contain the same active ingredient (tirzepatide) but differ in delivery and dose flexibility:

For patients on compounded tirzepatide, the dosage chart in this article still applies as a target reference. The same 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg progression is used, just drawn from a vial rather than delivered by pen.

For unit-to-mg conversion at compounded concentrations, see our tirzepatide units chart guide.

FAQ

What is the starting dose of Zepbound? The starting dose is 2.5 mg once weekly for 4 weeks. This is a tolerance dose, not a treatment dose. After 4 weeks, the dose increases to 5 mg, which is the first true treatment dose.

What is the maximum dose of Zepbound? The maximum FDA-approved dose is 15 mg once weekly. Higher doses have been studied in earlier-phase work for diabetes but are not approved for obesity treatment.

How often is Zepbound taken? Once weekly. The same day each week, with 7 days between doses. Tirzepatide has a half-life of about 5 days, which provides steady weekly coverage.

Do I have to escalate to 15 mg of Zepbound? No. Many patients reach their goal weight at 5 or 10 mg without needing higher doses. Escalation is based on whether the current dose is producing the needed weight loss, not on completing all label steps.

Can I skip the 7.5 mg or 12.5 mg dose? Sometimes. The label allows direct escalation from 5 mg to 10 mg, or from 10 mg to 15 mg, if the patient is tolerating well. The intermediate doses exist to give a softer step for patients with side-effect sensitivity.

How much weight will I lose at each Zepbound dose? Mean weight loss at 72 weeks in SURMOUNT-1: 16.0% at 5 mg, 21.4% at 10 mg, 22.5% at 15 mg. Individual responses vary widely. Type 2 diabetes patients lose about 60 to 70% as much at each dose.

What time of day should I inject Zepbound? Any time of day. Many patients inject in the evening so that any peak nausea occurs during sleep. Consistency on the day matters more than time of day.

Can I change my Zepbound injection day? Yes, with one constraint: leave at least 3 days between injections. If you usually inject on Mondays and want to switch to Thursdays, inject on the new day after at least 3 days have passed since the last dose.

What happens if I take two doses of Zepbound in one week? You will likely experience increased nausea, vomiting, and diarrhea. Doubling up is not dangerous in most cases but is not recommended. Skip the next scheduled dose to keep weekly spacing reasonable, then resume your normal schedule.

Is the Zepbound dosage chart the same for compounded tirzepatide? The dose targets are similar, but compounded tirzepatide is drawn from a vial in custom amounts rather than delivered by fixed-dose pen. Compounded medications are not FDA-approved and have not been tested in the same trials as Zepbound.

Why does my pen color look different from last month? Eli Lilly occasionally updates packaging. The dose printed on the pen and on the carton is what matters. Color is a visual cue, not the official identifier.

Can I keep my Zepbound pen out of the refrigerator? Yes, for up to 21 days at temperatures up to 86°F. Useful for travel. Do not refrigerate again after warming. Discard if exposed to higher temperatures or to freezing.

Sources (numbered list, no hyperlinks needed)

1. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.
2. Garvey WT, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402:613-626.
3. Wadden TA, et al. Tirzepatide after intensive lifestyle intervention (SURMOUNT-3). Nat Med. 2023;29:2909-2918.
4. Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction (SURMOUNT-4). JAMA. 2024;331:38-48.
5. Eli Lilly. Zepbound (tirzepatide) prescribing information. FDA approval label, current revision.
6. Frias JP, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). N Engl J Med. 2021;385:503-515.
7. Wharton S, et al. Real-world effectiveness of tirzepatide for obesity. Obesity (Silver Spring). 2024;32:687-697.
8. American Gastroenterological Association. Pharmacologic management of obesity 2022.
9. American Diabetes Association. Standards of Medical Care in Diabetes 2024. Diabetes Care. 2024;47(Suppl 1).

Footer disclaimers (all 4 verbatim)

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound is a registered trademark of Eli Lilly and Company. Other brand names referenced are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.